CGEM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CGEM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the three months ended in Mar. 2024, Cullinan Therapeutics paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Cullinan Therapeutics spent $0.00 Mil on financial activities for the three months ended in Mar. 2024.
The historical data trend for Cullinan Therapeutics's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash Flow from Financing | Get a 7-Day Free Trial | 85.72 | 140.14 | 268.78 | -25.93 | 40.75 |
Cullinan Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Flow from Financing | Get a 7-Day Free Trial | 1.79 | 38.60 | 0.11 | 0.25 | 1.09 |
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cullinan Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing | (A: Dec. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 38.388 | + | 0 | + | 1.825 | + | 0 | + | 0 | + | 0.538 |
= | 40.75 |
Cullinan Therapeutics's Cash from Financing for the quarter that ended in Mar. 2024 is:
Cash Flow from Financing | (Q: Mar. 2024 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 0 | + | 0 | + | 0 | + | 0 | + | 0 | + | 0 |
= | 0.00 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics (NAS:CGEM) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Cullinan Therapeutics's issuance of stock for the three months ended in Mar. 2024 was $0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Cullinan Therapeutics's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Cullinan Therapeutics's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. Cullinan Therapeutics received $0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Cullinan Therapeutics's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Cullinan Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Cullinan Therapeutics's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Cullinan Therapeutics received $0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Cullinan Therapeutics's other financing for the three months ended in Mar. 2024 was $0.00 Mil. Cullinan Therapeutics received $0.00 Mil on other financial activities.
Thank you for viewing the detailed overview of Cullinan Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Nadim Ahmed | director, officer: President and CEO | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Jacquelyn L Sumer | officer: Chief Legal Officer | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140 |
Jeffrey Alan Jones | officer: Chief Medical Officer | ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142 |
Jennifer Michaelson | officer: See Remarks | C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142 |
Jeffrey Trigilio | officer: Chief Financial Officer | C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142 |
David P. Ryan | director | C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142 |
Vision Scs F2 | 10 percent owner | 74 GRAND RUE, LUXEMBURG N4 L-1660 |
Savill Corrine | officer: Acting Chief Business Officer | C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142 |
F2 Bioscience I 2017 Ltd | 10 percent owner | 8, RUE SAINT-LEGER, GENEVA V8 CH 1205 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Anne-marie Martin | director | ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142 |
Mark N Lampert | 10 percent owner | 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104 |
Biotechnology Value Trading Fund Os Lp | other: See Explanation of Responses | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Bvf Partners Os Ltd. | other: See Explanation of Responses | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Biotechnology Value Fund Ii Lp | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
From GuruFocus
By sperokesalga sperokesalga • 03-27-2023
By sperokesalga sperokesalga • 02-27-2023
By GlobeNewswire GlobeNewswire • 01-03-2023
By sperokesalga sperokesalga • 05-25-2023
By Value_Insider Value_Insider • 11-01-2022
By Stock market mentor Stock market mentor • 01-24-2023
By Marketwired • 08-10-2023
By GlobeNewswire GlobeNewswire • 11-01-2022
By GlobeNewswire • 12-18-2023
By Marketwired • 09-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.